Research programme: cephalosporin antibacterials - Procter and Gamble
Alternative Names: 3-dithiocarbamoylcarbacephalosporins research programme - Procter and Gamble; Antibacterials research programme - Procter and Gamble; PGE 6737410; PGE 856854; PGE 9739390; PGE 9882816; PGE 9951357Latest Information Update: 05 Mar 2003
At a glance
- Originator Procter & Gamble
- Class
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 05 Mar 2003 No development reported - Preclinical for Gram-positive infections in USA (unspecified route)
- 16 Oct 2000 Preclinical development for Gram-positive infections in USA (Unknown route)